Sangamo Therapeutics (SGMO) Reports Q2 Loss of $0.26

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. PLTR
4. SPY
5. CSCO
6. KTOS
7. AON
8. TMUS
9. ALHC
10. LBRX

Go back to Sangamo Therapeutics (SGMO) Reports Q2 Loss of $0.26

Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results

August 5, 2020 4:01 PM EDT

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights.

We are very excited about our global collaboration agreement announced with Novartis last week. This is our second impactful partnership announced this year, and we believe it affirms the value our industry sees in our zinc finger technology, said Sandy Macrae, CEO of Sangamo. By advancing our robust partnership strategy, we proactively expand our genomic medicines... More